Rheumatoid arthritis (RA) is a chronic autoimmune condition that affects millions worldwide. According to the World Health Orgnization, 18 million people worldwide were living with the condition in ...

The emotional and physical toll doctors battle when they fall sick and become patients, facing the same fears and ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Rheumatoid arthritis is an autoimmune condition that causes the body’s immune system to attack its own joints, leading to ...

As millions of Americans experience the benefits of weight loss through the use of GLP-1 medications, some orthopedic experts are still torn on the potential effects the medications will have for ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according ...

Mikkel Damsgaard sits fourth in the Premier League assists chart in a stunning season for Brentford; the Danish midfielder ...

Celltrion announced on Friday that its biosimilar Avtozma, a version of the autoimmune disease treatment Actemra (active ingredient tocilizumab), has received product approval from the US Food and ...